Phase 1 Trial of IRAK4 Degrader KT-474 in Healthy Volunteers & Patients with Atopic Dermatitis & Hidradenitis Suppurativa

Time: 3:35 pm
day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

Details:

• Interim data from Healthy Volunteer SAD and MAD portions of the trial
• Data to include safety, PK, and PD establishing proof-of-mechanism and proof-of-biology

Speakers: